Search
Follow us: 
 

Success Factors and Failure Points in Oncology Product Launches

      
      

Features:
 58 Info Graphics
 82 Data Graphics
 750+ Metrics
 44 Narratives
 25 Best Practices

Pages: 173

Delivery Format: Shipped


Download Free Excerpt



Call 919-403-0251




Success Factors and Failure Points in Oncology Product Launches

ID: PSM-267

Price: 

Add to Cart

The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area. Launch results have been mixed with both instant successes and slow starters.

Recent market entries have illustrated that there is a critical core set of factors for oncology
products as well as other therapeutic areas: the ability to differentiate, a defined target patient population, investment in launch activities, engagement of thought leaders, education of key stakeholders, demonstration of value, utilization of new technologies and avoidance of launch pitfalls.

Best Practices, LLC's report, Success Factors and Failure Points in Oncology Product Launches, explores each aspect of this framework for launch success and provides an oncology segment as well as a data segment representing other therapeutic areas combined. This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.

In addition, the study presents launch leaders' perspective on the current and future risk levels for an array of pitfall factors that can affect a launch, from patient and payer to physician and regulatory.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical; Manufacturing; Diagnostic; Consumer Products; Media

Companies Profiled:
GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; AstraZeneca; Genentech; Phillips; TGC MedTech; MedImmune; Abbott; Amgen; Bayer; Actelion; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Bayer Schering Pharma; Quintiles; MerckSerono; Servier; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Urologix; Synapse biomedical; Talecris; NicOx; Eisai; Direct Supply; Shire; ChemGenex Pharmaceuticals; Takeda Pharmaceuticals

Study Snapshot

The new product launch landscape for oncology products and other therapeutic areas has never been more challenging with launch teams facing more potential pitfalls than ever. Best Practices®, LLC conducted this timely new benchmarking study to probe critical launch failure points and success factors.


Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 launch leaders from 38 different companies from the pharmaceutical, biotechnology and medical device sectors contributed data, reflecting on almost 30 products. In-depth interviews were conducted with veteran leaders from six organizations.

Key Findings

Differentiating Your Product - Secondary Benefits Can Be Win Themes: Differentiated positioning begins on factors established in clinical trials – such as efficacy, unmet needs, safety and target patient population. Secondary positioning factors have less overall impact – but can be useful in a crowded market – and are often more directly influenced through Marketing. Using secondary benefits can be an effective strategy for positioning a product in a highly competitive market.

Market Entry Requires Investing At and Above Market Leader Levels To Win Share of Voice: More than half of the Total Benchmark Class – 64 percent - favors spending 101 percent to 150 percent of the market leader’s investment level during product launch. Four out of five Oncology segment members favored investment levels of 101% to 150%. It was also the only segment that did not suggest an investment level of more than 151% of the market leader’s investment level.
Table of Contents


Background
  • Summary of Business Issues, Key Insights, Findings and Lessons Learned p. 4-17
  • Universe of Learning: Research Participants, Launch Experience, Oncology & Other Therapeutic Area Demographics p. 18-24
Main Deck
  • Winning on Differentiated Product Positioning p. 25-32
  • Winning a Physician’s Initial Trial of a New Product p. 33-35
  • Articulating Benefits that Shape Positive Market Perception p. 36-40
  • New Product Pricing Strategy p. 41-51
  • Thought Leader Engagement p. 52-59
  • Early Physician Education p. 60-70
  • Payer Education p. 71-75
  • Patient Advocacy and Education p. 76-80
  • Preparing Market Constituents p. 81-85
  • Access Insights & Success Factors p. 86-93
  • Winning Hospital Formulary Access p. 94-96
  • Resource Allocation for Key Stakeholders in the Current & Future Marketplaces p. 97-99
  • Investment Requirements, Resource Allocation & Timing p. 100-110
  • Internal Launch Readiness p. 111-124
  • New Technologies for Informing Patients & Physicians p. 125-130
  • Pitfalls & Stumbling Blocks p. 131-150
  • Demonstrating Efficacy p. 151-159
  • Rating Different Safety Dimensions p. 160-169
  • Lessons Learned, Best Practices & Future Changes p. 170-172
  • About Best Practices, LLC p. 173

Related Research

Excellent clinical trials can significantly reduce costs by preventing delayed product launch due to trial length... (ID OPS-85)
Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, AAI Corporation, AAI Development, read more ...

Price: $23100.00   Free Excerpt Available

A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Companies Profiled: aaiPharma, Sanofi-aventis, Abbott, Abbott Laboratories, read more ...

Price: $21100.00   Free Excerpt Available

Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, aaiPharma, Abbott Laboratories, read more ...

Price: $20735.00   Free Excerpt Available

Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, AstraZeneca, Bristol-Myers Squibb, read more ...

Price: $18400.00

Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Alcon, read more ...

Price: $9000.00   Free Excerpt Available

The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, read more ...

Price: $8500.00   Free Excerpt Available

The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, read more ...

Price: $8500.00   Free Excerpt Available

The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, read more ...

Price: $8500.00   Free Excerpt Available

The last several years have been marked by dozens of pharmaceutical product launches; some products took off at launch while many others fell flat... (ID PSM-261)
Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, read more ...

Price: $8500.00   Free Excerpt Available

In today’s pharmaceutical industry–where the recent product launch landscape is marked by as many failures as successes—it is critical for launch teams to understand the right level of resources required to give each new product its best chance for gaining a market foothold... (ID PSM-262)
Companies Profiled: Abbott, ProStrakan, Sanofi-aventis, Regeneron, read more ...

Price: $8000.00   Free Excerpt Available

The bio-pharmaceutical marketplace continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-248)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., read more ...

Price: $8000.00   Free Excerpt Available

The bio-pharmaceutical marketplace – including the diabetes therapeutic area – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-246)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., read more ...

Price: $8000.00   Free Excerpt Available

The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-243)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., read more ...

Price: $8000.00   Free Excerpt Available

The findings in this Best Practices Benchmarking® Report will enable pharmaceutical executives to understand the winning strategies, practices, team structures and investment patterns that distinguish successful new product development and marketing planning... (ID SM-124)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Bristol-Myers Squibb, Amgen, read more ...

Price: $7962.00   Free Excerpt Available

Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID SM-176)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, read more ...

Price: $7795.00   Free Excerpt Available

Patient and professional advocacy groups play a crucial role in educating the marketplace on new medicines and treatments... (ID SM-185)
Companies Profiled: Abaxis, Abbott Laboratories, Allos Therapeutics, Amgen, read more ...

Price: $7500.00   Free Excerpt Available

When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID POP-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, read more ...

Price: $7400.00   Free Excerpt Available

Educating the marketplace about disease state is crucial to the success of a new pharmaceutical product— especially if the product treats a medical condition that is previously unknown, socially sensitive or stigmatized or if the product is first in its class... (ID OP-106)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, read more ...

Price: $7200.00   Free Excerpt Available


 
ACCESS AND INTELLIGENCE FOR ACHIEVING WORLD-CLASS EXCELLENCE
Quick Links

Follow us: 

All contents copyright 1998-2020 Best Practices, LLC (919) 403-0251
Read our Terms and Conditions of Use, Privacy Policy and Copyright Information